Reply to: “Biologics for psoriasis during COVID-19 outbreak” - 19/04/20
Doi : 10.1016/j.jaad.2020.04.014
Dedee F. Murrell, MA, BMBCh, MD, FRCP a, Ryan Rivera-Oyola, MS b, ⁎ 
, Mark Lebwohl, MD b
, Mark Lebwohl, MD b a Department of Dermatology, St George Hospital, University of New South Wales, Sydney, Australia
b The Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai Hospital, New York, New York
∗Correspondence to: Ryan Rivera-Oyola, MS, The Kimberly and Eric J. Waldman Department of Dermatology, 5 E 98th St, 5th Floor, New York, NY, 10029The Kimberly and Eric J. Waldman Department of Dermatology5 E 98th St, 5th FloorNew YorkNY10029
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Sunday 19 April 2020
Le texte complet de cet article est disponible en PDF.
| Funding sources: None. |
|
| Conflicts of interest: Dr Murrell is an employee of St George Hospital, has been an investigator/advisor for Novartis, Sun Pharma, Janssen, and AbbVie, and is also the director of a clinical trial center for dermatologic diseases. Dr Lebwohl is an employee of Mount Sinai Hospital, receives research funds from AbbVie, Amgen, Eli Lilly, Janssen Research & Development, LLC, Novartis, Ortho Dermatologics, and UCB, Inc, and has been the principal investigator for numerous clinical trials but has no personal financial gain. Mr Rivera-Oyola has no relevant conflicts of interest to disclose. |
|
| IRB approval status: Not applicable. |
|
| Reprints not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Bienvenue sur EM-consulte, la référence des professionnels de santé.